# Veritone, Inc.: financial statements, quarterly

VERI · Nasdaq · CIK 1615165 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/veri.md) · [Financials](/companies/veri/financials.md) · [Filings](/companies/veri/filings.md) · [Insiders](/companies/veri/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/veri/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [28.0](/filings/0000950170-24-125533.md) | [27.1 d](/filings/0000950170-25-048602.md) | [24.2](/filings/0000950170-25-069243.md) | [24.1](/filings/0001615165-25-000012.md) | [22.0](/filings/0001628280-26-025211.md) | [22.4 d](/filings/0001628280-26-025214.md) | [22.5](/filings/0001628280-26-035074.md) | [23.2](/filings/0001628280-26-056828.md) | [26.6](/filings/0001628280-26-025211.md) | [19.9 d](/filings/0001628280-26-025214.md) | [20.3](/filings/0001628280-26-035074.md) | [24.3](/filings/0001628280-26-056828.md) |
| Cost of revenue | $m | [7.0](/filings/0000950170-24-125533.md) | [6.9 d](/filings/0000950170-24-038819.md) | [7.0](/filings/0000950170-24-057780.md) | [6.6](/filings/0000950170-24-096973.md) | [6.3](/filings/0000950170-24-125533.md) | not reported | not reported | [6.4](/filings/0001628280-26-056828.md) | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [10.4](/filings/0000950170-24-125533.md) | [8.1 d](/filings/0000950170-25-048602.md) | [8.4](/filings/0000950170-25-069243.md) | [6.1](/filings/0001615165-25-000012.md) | [6.8](/filings/0001628280-26-025211.md) | [5.5 d](/filings/0001628280-26-025214.md) | [5.2](/filings/0001628280-26-035074.md) | [4.9](/filings/0001628280-26-056828.md) | [5.5](/filings/0001628280-26-025211.md) | [5.1 d](/filings/0001628280-26-025214.md) | [5.8](/filings/0001628280-26-035074.md) | [5.9](/filings/0001628280-26-056828.md) |
| Operating income | $m | [(25.2)](/filings/0000950170-24-125533.md) | [(19.8) d](/filings/0000950170-25-048602.md) | [(24.4)](/filings/0000950170-25-069243.md) | [(20.3)](/filings/0001615165-25-000012.md) | [(22.5)](/filings/0001628280-26-025211.md) | [(21.0) d](/filings/0001628280-26-025214.md) | [(21.6)](/filings/0001628280-26-035074.md) | [(19.0)](/filings/0001628280-26-056828.md) | [(18.2)](/filings/0001628280-26-025211.md) | [(22.4) d](/filings/0001628280-26-025214.md) | [(19.4)](/filings/0001628280-26-035074.md) | [(22.1)](/filings/0001628280-26-056828.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(1.0)](/filings/0000950170-24-125533.md) | [(0.7) d](/filings/0000950170-25-048602.md) | [(1.0)](/filings/0000950170-25-069243.md) | [(0.1)](/filings/0001615165-25-000012.md) | [(2.6)](/filings/0001628280-26-025211.md) | [(0.1) d](/filings/0001628280-26-025214.md) | [(0.3)](/filings/0001628280-26-035074.md) | [0.9](/filings/0001628280-26-056828.md) | [(0.3)](/filings/0001628280-26-025211.md) | [(0.5) d](/filings/0001628280-26-025214.md) | [(0.6)](/filings/0001628280-26-035074.md) | [(0.3)](/filings/0001628280-26-056828.md) |
| Net income | $m | [(24.5)](/filings/0000950170-24-125533.md) | [12.2 d](/filings/0000950170-25-048602.md) | [(25.2)](/filings/0001628280-26-025211.md) | [(22.2)](/filings/0001628280-26-025211.md) | [(21.7)](/filings/0001628280-26-025211.md) | [31.8 d](/filings/0001628280-26-025214.md) | [(19.9)](/filings/0001628280-26-056828.md) | [(26.5)](/filings/0001628280-26-056828.md) | [(29.2)](/filings/0001628280-26-025211.md) | [(36.1) d](/filings/0001628280-26-025214.md) | [(19.5)](/filings/0001628280-26-056828.md) | [(22.2)](/filings/0001628280-26-056828.md) |
| Diluted EPS | $ per share | [(0.66)](/filings/0000950170-24-125533.md) | not reported | [(0.67)](/filings/0000950170-25-069243.md) | [(0.59)](/filings/0001615165-25-000012.md) | [(0.57)](/filings/0000950170-24-125533.md) | not reported | [(0.41)](/filings/0001628280-26-035074.md) | [(0.53)](/filings/0001628280-26-056828.md) | not reported | not reported | [(0.21)](/filings/0001628280-26-035074.md) | [(0.24)](/filings/0001628280-26-056828.md) |
| Basic EPS | $ per share | [(0.66)](/filings/0000950170-24-125533.md) | not reported | [(0.67)](/filings/0000950170-25-069243.md) | [(0.59)](/filings/0001615165-25-000012.md) | [(0.57)](/filings/0001628280-26-025211.md) | not reported | [(0.41)](/filings/0001628280-26-035074.md) | [(0.53)](/filings/0001628280-26-056828.md) | [(0.45)](/filings/0001628280-26-025211.md) | not reported | [(0.21)](/filings/0001628280-26-035074.md) | [(0.24)](/filings/0001628280-26-056828.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [72.1](/filings/0000950170-23-063678.md) | [46.6](/filings/0000950170-25-048602.md) | [90.7](/filings/0000950170-24-057780.md) | [46.0](/filings/0000950170-24-096973.md) | [11.4](/filings/0000950170-24-125533.md) | [16.9](/filings/0001628280-26-025214.md) | [16.1](/filings/0000950170-25-069243.md) | [13.6](/filings/0001615165-25-000012.md) | [36.2](/filings/0001628280-26-025211.md) | [27.4](/filings/0001628280-26-056828.md) | [15.1](/filings/0001628280-26-035074.md) | [12.4](/filings/0001628280-26-056828.md) |
| Current assets | $m | [161](/filings/0000950170-23-063678.md) | [186](/filings/0000950170-25-048602.md) | [172](/filings/0000950170-24-057780.md) | [142](/filings/0000950170-24-096973.md) | [165](/filings/0000950170-24-125533.md) | [59.4](/filings/0001628280-26-025214.md) | [61.3](/filings/0000950170-25-069243.md) | [57.2](/filings/0001628280-26-056828.md) | [83.7](/filings/0001628280-26-025211.md) | [73.9](/filings/0001628280-26-056828.md) | [50.5](/filings/0001628280-26-035074.md) | [47.5](/filings/0001628280-26-056828.md) |
| Total assets | $m | [359](/filings/0000950170-23-063678.md) | [379](/filings/0000950170-25-048602.md) | [360](/filings/0000950170-24-057780.md) | [322](/filings/0000950170-24-096973.md) | [336](/filings/0000950170-24-125533.md) | [198](/filings/0001628280-26-025214.md) | [200](/filings/0000950170-25-069243.md) | [188](/filings/0001628280-26-056828.md) | [199](/filings/0001628280-26-025211.md) | [182](/filings/0001628280-26-056828.md) | [155](/filings/0001628280-26-035074.md) | [148](/filings/0001628280-26-056828.md) |
| Current liabilities | $m | [186](/filings/0000950170-23-063678.md) | [192](/filings/0000950170-25-048602.md) | [198](/filings/0000950170-24-057780.md) | [182](/filings/0000950170-24-096973.md) | [249](/filings/0000950170-24-125533.md) | [61.0](/filings/0001628280-26-025214.md) | [62.1](/filings/0000950170-25-069243.md) | [63.8](/filings/0001628280-26-056828.md) | [63.6](/filings/0001628280-26-025211.md) | [104](/filings/0001628280-26-056828.md) | [96.3](/filings/0001628280-26-035074.md) | [101](/filings/0001628280-26-056828.md) |
| Total liabilities | $m | [341](/filings/0000950170-23-063678.md) | [341](/filings/0000950170-25-048602.md) | [345](/filings/0000950170-24-057780.md) | [327](/filings/0000950170-24-096973.md) | [362](/filings/0000950170-24-125533.md) | [185](/filings/0001628280-26-025214.md) | [185](/filings/0000950170-25-069243.md) | [185](/filings/0001628280-26-056828.md) | [183](/filings/0001628280-26-025211.md) | [114](/filings/0001628280-26-056828.md) | [106](/filings/0001628280-26-035074.md) | [111](/filings/0001628280-26-056828.md) |
| Long-term debt | $m | not reported | [77.5](/filings/0000950170-24-038819.md) | [77.5](/filings/0000950170-24-057780.md) | [75.6](/filings/0000950170-24-096973.md) | [73.6](/filings/0000950170-24-125533.md) | [41.2](/filings/0000950170-25-048602.md) | [39.2](/filings/0000950170-25-069243.md) | [37.3](/filings/0001615165-25-000012.md) | [35.4](/filings/0001628280-26-025211.md) | not reported | not reported | not reported |
| Shareholders' equity | $m | [18.7](/filings/0000950170-24-125533.md) | [38.1](/filings/0001628280-26-025214.md) | [14.9](/filings/0001628280-26-025211.md) | [(5.7)](/filings/0001628280-26-025211.md) | [(25.2)](/filings/0001628280-26-025211.md) | [13.5](/filings/0001628280-26-056828.md) | [14.8](/filings/0001628280-26-056828.md) | [3.5](/filings/0001628280-26-056828.md) | [15.5](/filings/0001628280-26-025211.md) | [68.1](/filings/0001628280-26-056828.md) | [49.0](/filings/0001628280-26-056828.md) | [37.9](/filings/0001628280-26-056828.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [10.4 d](/filings/0000950170-24-125533.md) | [(28.3) d](/filings/0000950170-25-048602.md) | [14.9](/filings/0000950170-25-069243.md) | [(42.7) d](/filings/0001615165-25-000012.md) | [3.6 d](/filings/0001628280-26-025211.md) | [(0.5) d](/filings/0001628280-26-025214.md) | [(17.0)](/filings/0001628280-26-035074.md) | [(8.2) d](/filings/0001628280-26-056828.md) | [(15.9) d](/filings/0001628280-26-025211.md) | [(12.0) d](/filings/0001628280-26-025214.md) | [(11.5)](/filings/0001628280-26-035074.md) | [(10.6) d](/filings/0001628280-26-056828.md) |
| Capital expenditure | $m | [1.4 d](/filings/0000950170-24-125533.md) | [0.7 d](/filings/0000950170-25-048602.md) | [1.8](/filings/0000950170-25-069243.md) | [1.4 d](/filings/0001615165-25-000012.md) | [1.7 d](/filings/0001628280-26-025211.md) | [1.2 d](/filings/0001628280-26-025214.md) | [1.4](/filings/0001628280-26-035074.md) | [1.0 d](/filings/0001628280-26-056828.md) | [1.2 d](/filings/0001628280-26-025211.md) | [1.4 d](/filings/0001628280-26-025214.md) | [0.5](/filings/0001628280-26-035074.md) | [1.5 d](/filings/0001628280-26-056828.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | billions of shares | [0.0](/filings/0000950170-23-063678.md) | [0.0](/filings/0000950170-24-057780.md) | [0.0](/filings/0000950170-24-096973.md) | [0.0](/filings/0000950170-24-125533.md) | [0.0](/filings/0000950170-25-069243.md) | [0.0](/filings/0001615165-25-000012.md) | [0.0](/filings/0001628280-26-025211.md) | [48.3](/filings/0001628280-26-035074.md) | [0.0](/filings/0001628280-26-056828.md) | [0.1](/filings/0001628280-26-025211.md) | [92.9](/filings/0001628280-26-035074.md) | [0.1](/filings/0001628280-26-056828.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 100,457,068 at 2026-08-11, from the cover of the [10-Q filed 2026-08-13](/filings/0001628280-26-056828.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.